Corynebacterium parvum in malignant pleural effusion. A randomized prospective study

Area of Science:

• Oncology
• Pulmonology
• Clinical Trials

Background:

• Malignant pleural effusion is a common complication of cancer.
• Repeated drainage is often required, impacting patient quality of life.
• Effective pleurodesis is crucial for managing malignant pleural effusion.

Purpose of the Study:

• To compare the efficacy of Corynebacterium parvum versus bleomycin for pleurodesis in patients with malignant pleural effusion.
• To evaluate the number of treatments required for successful pleurodesis with each agent.

Main Methods:

• A randomized trial involving 32 patients with malignant pleural effusion.
• Patients received intrapleural instillation of either Corynebacterium parvum or bleomycin after pleural fluid drainage.
• Efficacy was assessed by the need for further drainage treatments.

Main Results:

• Corynebacterium parvum demonstrated significantly higher efficacy (p < 0.001).
• 65% of C. parvum patients achieved pleurodesis after one treatment, with an additional 29% after two.
• Only 2 out of 15 bleomycin patients achieved pleurodesis after one treatment; 13 required further interventions.

Conclusions:

• Corynebacterium parvum is a highly effective agent for pleurodesis in malignant pleural effusion.
• C. parvum offers a superior treatment option compared to bleomycin, requiring fewer interventions.
• This study highlights the significant benefit of C. parvum in managing malignant pleural effusions.